fbpx
E-SCIENCE WEBINAR 6
Thank you for joining webinar
Webinar recording will be available on the website soon
circle-cropped31.png
user
Prof Luis H.W. Gowdak(CHAIR)
Brazil
Giuseppe-Rosano-Pic
user
Prof G. Rosano
(UK)
Manolis
user
Prof. Athanasios J. Manolis
Greece
circle-cropped32.png
user
Prof Luis H.W. Gowdak(CHAIR)
Brazil
Giuseppe-Rosano-Pic
user
Juan Prof G. Rosano
UK
Manolis
user
Prof. Athanasios J. Manolis
Greece
Interactive E-Science Webinar 07
Ischemia with Non Obstructive Coronary Artery disease (INOCA)

Crosstalks between patients and doctors
9 December 2021 | 12H (noon) CET
Chairs
Group 127
user
G. Rosano (UK)
Group 126
user
M. Marzilli (Italy)
Introduction (M. Marzilli)
Pathophysiology of INOCA (J.C. Kaski)
Discussion
Patients perspectives (Maria George – INOCA International)
Management of INOCA (M. Marzilli)
Discussion
Conclusion (G. Rosano)
E-Science Webinar 06
Individualised treatment of patients with Angina and HF where do we stand after ESC 2021
Individualised treatment of patients with Angina and HF where do we stand after ESC 2021
9 July 2021 – 14.00-15:30 CEST (Paris time)
( Chair )
Filippo
user
Filippo Crea,
Italy
Reappraisal of optimal medical therapy vs PCI in chronic coronary syndromes
Mutlu
user
Bülent Mutlu,
Turkey
Clinical case discussion
Abdelhamid.Magdy
user
Magdy Abdelhamid
(Egypt)
Panel discussion with speakers and international discussants
circle-cropped31.png
user
Luis Henrique Gowdak
(Brazil)
Panel discussion with speakers and international discussants
in collaboration with
Filippo
Past webinar
E-Science Webinar 04
Angina management in clinical practice: from prevention to symptoms control
27th of May – 2021
E-Science Webinar 05
Recent data about coronary revascularization
9th of July – 2021
E-Science Webinar 06
Individualised treatment of patients with Angina and HF where do we stand after ESC 2021
14th of October – 2021
Thank you for joining the E-Science Webinar 04
The next webinar will be on the 9th of July 2021, Keynote speaker : Prof Filippo Crea, Italy
in collaboration with
E-Science webinar 2
Management of post-PCI Angina
12 March 2021
circle-cropped2 op
user
Giuseppe Rosano UK
Abdelhamid.Magdy
user
Magdy Abdelhamid Egypt
circle-cropped3 op
user
Luis Henrique W. Gowdak Brazil
user
Interactive Discussion

Interactive E-Science Webinar 7
Crosstalks between patients and doctors
Ischemia with Non Obstructive Coronary Artery disease (INOCA)
G. Rosano
(UK)
Chairs
M. Marzilli
(Italy)

Introduction (M. Marzilli)

Pathophysiology of INOCA (J. C. Kaski)

Discussion

Patients perspectives
(Maria George - INOCA International)

Management of INOCA (M. Marzilli)

Discussion

Conclusion (G. Rosano)

9 December 2021 | 12H (noon) CET
new-cover-bg
Past Webinar

E-Science Webinar 04
Angina management in clinical
practice: from prevention to
symptoms control
27th of May - 2021

line2 View webinar
E-Science Webinar 05

Recent data about coronary
revascularization
9th of July - 2021
View webinar
E-Science Webinar 06

Individualised treatment of patients with
Angina and HF where do we stand after
ESC 2021
14th of October - 2021
View webinar line2
calanderNovember 2021

Medical education activity


Editor-image

In this activity about stable angina, the authors’ objectives are to identify and appropriately diagnose stable angina, to understand pathophysiology behind myocardial ischaemia to assist in treatment options, to identify and manage risk factors to decrease mortality risk with coronary heart disease, to stress the importance of utilising an interdisciplinary approach with individuals who have stable angina and multiple comorbidities in order to optimise outcomes.

Please start the course here

calanderBy S. Duartecalander15 November 2021

IN THE LITERATURE THIS WEEK


Featured image

Microvascular angina: quo tendimus?

Microvascular angina (MVA) is diagnostically defined as angina pectoris with myocardial ischaemia but without significant, i.e., obstructive epicardial coronary atherosclerotic disease. The pathophysiological mechanisms responsible for MVA are often not fully adressed in clinical practice and even though the high prevalence and increased healthcare burden associated with MVA are being increasingly recognized.

This editorial by Dr Cheng and Dr De Silva (Imperial College, London, UK) underscores current clinical knowledge on MVA following…

calanderBy Dr. Williamcalander23 December 2020

Medical Education


Angina ccs guidlines

There have been no landmark trials necessitating a major change regarding the drugs recommended for angina treatment since the 2013 guidelines. Newer second-line drugs such as nicorandil, ranolazine, ivabradine and trimetazidine, have class IIa recommendations when symptoms are not adequately controlled by first-line drugs and nitrates.

calanderBy Dr. Jadecalander23 December 2020

Angina In the world


Angina in brazil

Antithrombotic therapy: In earlier guidelines, aspirin was recommended in all patients with coronary artery disease. In the 2019 guideline, it is stated that “Aspirin 75‐100 mg daily is recommended in patients with a previous MI or revascularization and “Aspirin 75‐100 mg daily may be considered in patients without a history of MI or revascularization, but with definitive evidence of CAD on imaging.

Featured image
calanderBy Prof. G Rosanocalander24 November 2021
congress coverage eSPACE HF 2021

Prof Rosano, UK, reviews best practices for patients with heart failure and high heart rate. Guidelines should be implemented according to the profile of the patient, beta-blockers and ivabradine should be pursued.

Featured image
calanderBy Prof. Fausto Pintocalander5 September 2021
Prof. Fausto Pinto; Comment on a recent study published in the EHJ (European Heart Journal) by Navarese and colleagues

During the HFA conference in Florence, Italy, Prof. Fausto Pinto (Head of the cardiology department at the University Hospital in Lisbon, past president of the ESC and president of the World Heart Federation) commented on a recent study published in the EHJ (European Heart Journal) by Navarese and colleagues. This systematic review and meta-analysis compared the differences between 2 strategies in managing stable patients with coronary artery disease: elective coronary revascularization plus medical therapy over medical therapy alone and the results are quite interesting.

Featured image
calanderBy Prof. C Rosanocalander8 July 2021
PATIENTS WITH HEART FAILURE AND ISCHEMIC HEART DISEASE

Prof Rosano from Florence during HFA conference 2021.During the Heart Failure 2021 & World Congress on Acute Heart Failure held in Florence from 29 June to 1st July 2021, Prof Rosano discusses recommendations for patients with heart failure and ischemic heart disease.

RSS Follow latest articles on microvascular angina
Featured image
calanderBy G. Bozet, MDcalander15 November 2021
Biomarkers of Coronary Microvascular Dysfunction in Patients With Microvascular Angina: A Narrative Review

Coronary microvascular dysfunction (CMD) is the main mechanism underlying microvascular angina (MVA), i.e. myocardial ischemia without significant flow-limiting obstructive coronary artery disease (CAD). Invasive methods, such as reactivity testing using acetylcholine or adenosine during coronary angiography, are the current gold standard for CMD diagnosis in the absence of myocardial diseases.

Featured image
calanderBy G. Bozet, MDcalander8 November 2021
Chronic coronary syndrome patients: can revascularisation reduce all-cause mortality?

As pointed by J. Gavara et al. (Universitat Politècnica de València, Valencia, Spain), the role of revascularisation in chronic coronary syndrome and the value of ischaemia vs. anatomy to guide decision-making are in constant debate.
For this reason, they explored the potential of “a combined assessment of ischaemic burden by vasodilator stress cardiovascular magnetic resonance and presence of multivessel disease by angiography to predict the effect of revascularisation on all-cause mortality in chronic coronary syndrome”.

Featured image
calanderBy G. Bozet, MDcalander2 November 2021
Utility of high-sensitivity troponin

Presentations with suspected stable angina are common yet determining an accurate diagnosis is frequently challenging. It is in this context that a role has emerged for the most recent generation of high-sensitivity cardiac troponin assays. High-sensitivity troponin (hsTn) has demonstrated prognostic value in stable outpatients with symptoms suggestive of coronary artery disease (CAD). A. Sharma et al. (McGill University, Montreal, Quebec, Canada) measured single molecule counting high-sensitivity troponin I in symptomatic outpatients in the PROMISE ((Prospective Multicenter Imaging Study for Evaluation of Chest Pain) study. The goal was to evaluate the hypothesis that hsTnI may identify patients who are unlikely to have inducible ischaemia on stress imaging or events and for which therefore testing is unlikely to be beneficial.

Featured image
calanderBy S. Duartecalander27 October 2021
ISCHEMIA trial: the endless story

Coronary artery disease (CAD) can cause angina, myocardial infarction, sudden death and heart failure. Its treatments include optimal medical therapy (OMT), surgical revascularization and percutaneous coronary intervention (PCI) revascularization.
This review by Santucci and Cavallini dissects the results of two studies, COURAGE (2007) and ISCHEMIA (2020), which compared an invasive strategy (selective coronary angiography and PCI revascularization) to a non-invasive one (OMT alone) in patients with myocardial ischemia due to CAD.

Featured image
calanderBy S. Duartecalander25 October 2021
Myocardial Ischemia in the Management of Chronic Coronary Artery Disease: Past and Present

Optimal treatment strategy for managing stable ischemic heart disease is still a topic of debate. The purpose of this review by P. Vafaei et al. (Kaiser Permanente San Francisco Medical Center, California USA) is to discuss treatment strategies for managing stable coronary artery disease. It reviews findings based on the COURAGE trial (2007) and ISCHEMIA trial (2020).
For the authors, when applied to a broad population with stable CAD, evidence suggests there is no benefit to an initial invasive revascularisation strategy relative to optimal medical therapy alone.

Featured image
calanderBy D. Beardcalander5 October 2021
Implications of the Landmark ISCHEMIA Trial on the Initial Management of High-Risk Patients with Stable Ischemic Heart Disease.

Optimal treatment strategy for managing stable ischemic heart disease is still a topic of debate. The purpose of this review by P. Vafaei et al. (Kaiser Permanente San Francisco Medical Center, California USA) is to discuss treatment strategies for managing stable coronary artery disease. It reviews findings based on the COURAGE trial (2007) and ISCHEMIA trial (2020.
For the authors, when applied to a broad population with stable CAD, evidence suggests there is no benefit to an initial invasive revascularisation strategy relative to optimal medical therapy alone.

Featured image
calanderBy D. Beardcalander5 September 2021
Stable angina and NSTEMI: plaque distribution and target vessel vulnerability

There is very little data comparing plaque characteristics and wire-free physiological assessment in the target vessel in patients with stable angina versus acute coronary syndrome.

In this study, K. Dan et al. (USA)investigated the difference in plaque distribution between stable angina and NSTEMI, and explored the relationship between target vessel vulnerability by optical coherence tomography and wire-free functional assessment with quantitative flow ratio.

Featured image
calanderBy G. Bozet, MDcalander2 September 2021
The Priority of Non-HDL-C Assessment to Predict New Lesions among Stable Angina Patients with Strong Statins

Dyslipidemia is known to be significantly associated with an increased risk of CAD and lipid-lowering strategy is the key approach for primary and secondary prevention.
In this cohort study, D. Kanda et al. (Kagoshima University, Japan) aimed to examine the clinical meaning of LDL-C <70 mg/dL and non-HDL-C <100 mg/dL on the occurrence of new lesions among Japanese patients with stable angina who were prescribed with strong statins.

Featured image
calanderBy D. Beardcalander2 September 2021
Blood urea nitrogen is associated with long-term all-cause mortality in stable angina pectoris patients: 8-year follow-up results

Elevation of blood urea nitrogen (BUN) indicates renal dysfunction and is associated with increased mortality in cardiovascular diseases.
The authors investigated the relationship between the blood urea nitrogen concentration measured at hospital admission and the long-term all-cause mortality in 344 patients with stable angina pectoris, during a mean follow-up period of 8 yrs.

Featured image
calanderBy admincalander11 June 2021
CONGRESS COVERAGE

E. Navarese et al. (Nicolaus Copernicus University, Poland) presented the results of a new meta-analysis of revascularisation plus medical therapy versus medical therapy alone in patients with chronic coronary syndromes. A total of 19,806 patients with chronic coronary syndromes undergoing elective revascularisation from 25 randomised trials were pooled.

Podcasts


Joints are the areas where two or more bones meet. Most joints are mobile, allowing the bones to move. Joints consist of the following: Cartilage – at the joint, the bones are covered with cartilage (a connective tissue), which is made up of cells and fibers and is wear-resistant. Cartilage helps reduce the friction of movement. Synovial membrane months, and years to a lifetime....
Featured image
calanderBy Dr. Williamcalander23 December 2020
Brazilian Society of Cardiology

biomarkers in angina

Emphasis is placed on the various lifestyle modifications as outlined in the recent lipids and preventive guidelines

Featured image
calanderBy Dr. Zephcalander23 December 2020
AHA 2021

What’s new in 2021

Despite significant advances in medical technology and pharmacology, cardiovascular disease remains a leading

Video


Video
author By Prof. G Rosano calander 4 December 2021
Cardiovascular disease remains the number one cause of death and disability around the globe.
Featured image
calanderBy Prof. G Rosanocalander24 November 2021
congress coverage eSPACE HF 2021

Prof Rosano, UK, reviews best practices for patients with heart failure and high heart rate. Guidelines should be implemented according to the profile of the patient, beta-blockers and ivabradine should be pursued.

Featured image
calanderBy Prof. G Rosanocalander20 September 2021
IN THE LITERATURE THIS WEEK        

Patient profiling in heart failure for tailoring medical therapy. The patients with HF and IHD / Angina.

The Heart failure association of the European society of cardiology recently published new guidelines for patients with heart failure as well as a consensus document on patients profiling. A very relevant question for clinical practice is how to implement therapies according to the profiles of the patients. Some have heart failure and ischemic heart disease/angina. Prof Rosano, UK shares some recent information.